Il Dong Pharmaceutical Co Ltd (249420.KS)
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩351.39B
₩599.82B
₩225.67B
₩10,300.00 - ₩20,500.00
₩50,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Il Dong Pharmaceutical Co Ltd (249420.KS) returned 6.88% year-to-date (YTD) and -7.77% over the past 12 months.
249420.KS
6.88%
6.34%
4.83%
-7.77%
-32.93%
-1.83%
N/A
^GSPC (Benchmark)
0.51%
5.49%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 249420.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -4.42% | 2.93% | -4.06% | 6.48% | 6.34% | 6.88% | |||||||
| 2024 | -15.14% | 1.88% | 0.32% | -1.40% | -12.17% | -4.69% | 7.15% | 8.76% | -8.38% | -2.02% | -11.76% | -1.92% | -35.19% |
| 2023 | -9.11% | -9.06% | -7.84% | -7.82% | -2.99% | -18.87% | 3.68% | -2.02% | 31.00% | -23.33% | 6.77% | 5.64% | -36.39% |
| 2022 | -4.02% | 81.71% | 16.38% | -26.98% | -16.27% | -26.02% | 29.82% | -7.62% | -24.32% | -1.79% | 39.64% | -25.65% | -15.03% |
| 2021 | -2.12% | -7.30% | -7.29% | -2.83% | -0.32% | 5.84% | -6.75% | -5.26% | -3.47% | 1.08% | 21.35% | 97.07% | 77.78% |
| 2020 | -6.27% | -13.38% | -2.72% | 2.78% | 6.56% | 8.33% | 6.69% | 15.67% | -8.67% | 2.08% | 13.66% | -3.32% | 18.48% |
| 2019 | -2.69% | 2.01% | 7.14% | 2.53% | -12.78% | 1.54% | -12.66% | -6.96% | -4.67% | 10.13% | -2.37% | 2.44% | -17.59% |
| 2018 | 19.87% | -14.44% | 4.58% | -0.80% | -8.23% | -6.56% | 4.22% | 12.58% | 7.19% | -28.86% | 15.71% | -0.85% | -6.36% |
| 2017 | -5.79% | 5.31% | 3.71% | 14.83% | 0.67% | -7.52% | -7.89% | 2.86% | -2.53% | 17.62% | 20.26% | -4.08% | 37.82% |
| 2016 | -10.63% | -22.47% | -3.41% | 24.76% | -16.50% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 249420.KS is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Il Dong Pharmaceutical Co Ltd (249420.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Il Dong Pharmaceutical Co Ltd provided a 0.00% dividend yield over the last twelve months, with an annual payout of ₩0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩95.24 | ₩380.95 | ₩362.81 | ₩224.88 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.60% | 1.96% | 1.71% | 1.44% |
Monthly Dividends
The table displays the monthly dividend distributions for Il Dong Pharmaceutical Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩95.24 | ₩95.24 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩380.95 | ₩380.95 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩362.81 | ₩362.81 |
| 2016 | ₩224.88 | ₩224.88 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Il Dong Pharmaceutical Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Il Dong Pharmaceutical Co Ltd was 86.09%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Il Dong Pharmaceutical Co Ltd drawdown is 83.34%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -86.09% | Apr 8, 2022 | 736 | Apr 9, 2025 | — | — | — |
| -63.53% | Apr 18, 2018 | 471 | Mar 19, 2020 | 430 | Dec 14, 2021 | 901 |
| -38.58% | Sep 1, 2016 | 64 | Dec 5, 2016 | 91 | Apr 17, 2017 | 155 |
| -33.2% | Jan 5, 2022 | 13 | Jan 21, 2022 | 6 | Feb 3, 2022 | 19 |
| -30.24% | Feb 8, 2022 | 6 | Feb 15, 2022 | 8 | Feb 25, 2022 | 14 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Il Dong Pharmaceutical Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Il Dong Pharmaceutical Co Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 45.5% positive surprise.
Valuation
The Valuation section provides an overview of how Il Dong Pharmaceutical Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 249420.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 249420.KS has a P/S ratio of 0.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 249420.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 249420.KS has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |